Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that affects multiple
organ systems and is caused by loss-of-function mutations in one of two genes: TSC1 or …

Tuberous sclerosis complex (TSC) is a genetic autosomal dominant disorder characterized
by benign tumor-like lesions, called hamartomas, in multiple organ systems, including the …

Importance Facial angiofibromas occur in approximately 75% of individuals with tuberous
sclerosis complex (TSC), causing substantial morbidity and disfigurement. Current therapies …

Abstract Background and Objectives Facial angiofibromas are disfiguring facial lesions,
present in up to 80% of patients with tuberous sclerosis complex. Recent elucidation of the …

Importance Inhibitors of mammalian target of rapamycin complex 1, such as sirolimus,
effectively target skin lesions in tuberous sclerosis complex (TSC). However, systemic …

Background Potential benefits of rapamycin or rapalogs for treating people with tuberous
sclerosis complex (TSC) have been shown. Currently everolimus (a rapalog) is only …

Abstract Background Facial angiofibromas (FAs) are a major feature of tuberous sclerosis
complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream …

Tuberous sclerosis complex is an autosomal dominant disease characterised by abnormal
cell proliferation and differentiation that affects multiple organs and can lead to the growth of …

Importance Most patients with tuberous sclerosis complex (TSC), an autosomal-dominant
disorder that is caused by the constitutive activation of mammalian target of rapamycin …

Background Systemic mammalian target of rapamycin (mTOR) inhibitors are currently used
in many dermatologic indications. Their topical use is recent and poorly codified. Objective …